OpenAI Acquires Orchestra Bio to Apply AI Operations to Life Sciences R&D

OpenAI announced on October 20, 2026, that it is acquiring Orchestra Bio, aiming to bring AI-powered operations to life sciences research and development. The acquisition is expected to help biopharma teams accelerate drug development and advance new treatments. OpenAI, a leading artificial intelligence company, has not disclosed further financial details of the transaction.